Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Yan Degenhardt et al.|Clinical Cancer Research|2011Cited by 168
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancerV Harding, Roshan Agarwal, Elisabetta Fenu et al.|British Journal of Cancer|2012Cited by 34
431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumorsSarah P. Blagden, Johann S. de Bono, David Olmos et al.|European Journal of Cancer Supplements|2008Cited by 4
Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancerSarah P. Blagden, Johann S. de Bono, David Olmos et al.|European Journal of Cancer Supplements|2008Cited by 2